After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

The company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including (osimertinib) and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu (trastuzumab ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

The question of putative mechanisms of action continues to haunt psychopharmacology. Put simply, we know these drugs work, but we have very little idea how. We make guesses based on the ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 positive, staying vigilant in looking for signs of adverse events (AEs) is ...

The pharmacokinetics of trastuzumab are not well-known. The volume of distribution approximates serum volume (44 mL/kg). [54] The elimination route has not been clearly defined. In studies in ...